Voyager Therapeutics 過去の業績
過去 基準チェック /06
Voyager Therapeuticsの収益は年間平均-24.4%の割合で減少していますが、 Biotechs業界の収益は年間 増加しています。収益は年間34.1% 4.5%割合で 減少しています。
主要情報
-24.38%
収益成長率
-13.52%
EPS成長率
| Biotechs 業界の成長 | 17.04% |
| 収益成長率 | -4.48% |
| 株主資本利益率 | -69.78% |
| ネット・マージン | -312.63% |
| 前回の決算情報 | 30 Jun 2026 |
最近の業績更新
Recent updates
分析記事 • Aug 12
Analysts Have Just Cut Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Revenue Estimates By 47%
Today is shaping up negative for Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) shareholders, with the analysts delivering...分析記事 • Aug 10
The Voyager Therapeutics, Inc. (NASDAQ:VYGR) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
It's been a good week for Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) shareholders, because the company has just...
ナラティブ更新 • Jun 22
VYGR: Tau Gene Therapy Pipeline Progress Will Drive Future Upside Potential
Analysts have kept their $25.00 price target on Voyager Therapeutics unchanged, citing largely consistent assumptions around fair value, revenue growth, profit margin, discount rate, and future P/E compared with prior estimates. What’s in the News for Voyager Therapeutics Voyager Therapeutics stockholders approved an amendment to the Fifth Amended and Restated Certificate of Incorporation on June 9, 2026, increasing authorized capital stock from 125,000,000 to 245,000,000 shares and authorized common stock from 120,000,000 to 240,000,000 shares, with the additional common stock carrying the same rights as existing shares.ナラティブ更新 • Jun 05
VYGR: Tau Gene Therapy Progress Will Drive Future Upside Potential
Analysts have adjusted their price target for Voyager Therapeutics to $25.00, reflecting updated views on the company’s revenue potential, profit margin outlook, and a lower estimated future P/E multiple. What's in the News U.S. Food and Drug Administration cleared Voyager Therapeutics' Investigational New Drug application for VY1706, an investigational tau silencing gene therapy for Alzheimer's disease, enabling the company to move ahead with clinical testing.分析記事 • May 07
Companies Like Voyager Therapeutics (NASDAQ:VYGR) Could Be Quite Risky
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...ナラティブ更新 • May 04
VYGR: Leadership Transition And Future P/E Stability Will Drive Upside
Analysts have maintained their $25.00 price target for Voyager Therapeutics, noting only minor adjustments to their model inputs, including a slightly different discount rate, revenue growth assumption, profit margin forecast, and future P/E multiple. What's in the News Chief Financial Officer Nathan Jorgensen, Ph.D. notified Voyager Therapeutics on April 15, 2026, that he will resign from his role and all other positions at the company, effective May 8, 2026, to pursue a new opportunity (Key Developments).ナラティブ更新 • Apr 19
VYGR: Future P/E Stability Will Drive Upside From Cash And Milestone Optionality
Analysts kept their price target for Voyager Therapeutics steady at $25.00, reflecting small tweaks to underlying assumptions, such as a slightly higher discount rate, modest adjustments to revenue growth and profit margin expectations, and a marginal shift in the very large future P/E input. Valuation Changes $Fair Value remained unchanged at $25.00.Seeking Alpha • Apr 13
Voyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026
Summary Voyager Therapeutics maintains a "Strong Buy" rating as it approaches a pivotal 2026 catalyst with tau PET imaging data from its phase 1b study in Alzheimer's disease. Company's anti-tau monoclonal antibody VY7523 demonstrated an excellent safety and PK profile in phase 1 SAD, enabling advancement to phase 1b MAD in early AD patients. Company's robust cash position, projected to fund operations into 2028, is further supported by potential $2.4B in milestone payments and ongoing collaborations. Additional upside exists with VY1706 tau-silencing gene therapy and multiple partnered programs, though key risks hinge on upcoming clinical data and regulatory milestones. Read the full article on Seeking Alphaナラティブ更新 • Apr 03
VYGR: Future P/E Stability Will Support Upside From Cash And Milestone Optionality
Analysts maintained their Voyager Therapeutics price target at $25.00, citing only minor adjustments in assumptions such as discount rate, revenue growth, profit margin and future P/E that did not materially affect their overall valuation view. Valuation Changes Fair Value: Held steady at $25.00 per share, with no change in the analysts' central estimate.ナラティブ更新 • Mar 19
VYGR: Higher Future P/E Will Support Upside From Cash And Milestone Optionality
Analysts have kept their Voyager Therapeutics price target steady at $25.00, with updated assumptions reflecting a slightly lower discount rate, more measured revenue growth, a much slimmer profit margin, and a very large projected future P/E multiple. Together, these factors signal a more cautious outlook on profitability while holding the same headline valuation.ナラティブ更新 • Mar 04
VYGR: Higher Future P/E Will Support Upside From Cash And Milestone Optionality
Analysts have kept their $25.00 price target for Voyager Therapeutics unchanged, citing updated assumptions around discount rate, revenue growth, profit margin, and future P/E that offset each other overall. Valuation Changes Fair Value: $25.00 unchanged, with the updated inputs offsetting each other in the model.ナラティブ更新 • Feb 17
VYGR: Refined Assumptions Will Reinforce Upside From Cash And Milestone Optionality
Analysts kept their $25.00 price target for Voyager Therapeutics unchanged, noting only very small tweaks in the discount rate, revenue growth assumptions, profit margin, and future P/E that do not materially alter their view. Valuation Changes Fair Value: Kept steady at $25.00, with no change in the estimated intrinsic value per share.ナラティブ更新 • Feb 03
VYGR: Neuro Data Readouts Will Reframe Upside From Cash And Milestone Optionality
Narrative Update Analysts trimmed their price target on Voyager Therapeutics to US$25 from US$30, citing the latest cash position of US$229m, potential partner milestones of up to US$2.4b, and progress in NeuroShuttle non viral delivery programs as key inputs to their updated outlook. Analyst Commentary Bullish analysts see the latest price target move to US$25 as a reset that still implies upside from current levels, supported by what they view as a solid capital position and a growing partnered pipeline.ナラティブ更新 • Jan 20
VYGR: Cash Strength And Milestone Upside Will Drive Neuro Data Repricing
Narrative Update on Voyager Therapeutics Analysts have trimmed their price target on Voyager Therapeutics to US$25 from US$30, citing strong Q3 cash of US$229m, eligibility for up to US$2.4b in partner milestones, and upcoming NeuroShuttle data as key factors shaping their outlook. Analyst Commentary Bullish analysts are adjusting their views while still highlighting what they see as solid execution and a meaningful cash position at Voyager Therapeutics.ナラティブ更新 • Jan 06
VYGR: Cash And Milestone Optionality Will Support Upcoming Neuro Data Repricing
Analysts have trimmed their price target on Voyager Therapeutics to US$25 from US$30, citing updated assumptions around future P/E multiples, while also highlighting the company’s Q3 cash position of US$229m, potential partner milestones of up to US$2.4b, and upcoming NeuroShuttle data as key drivers for the outlook. Analyst Commentary Bullish analysts continue to see a constructive setup for Voyager Therapeutics, even with the reduced price target, pointing to cash resources, milestone potential, and the NeuroShuttle platform as the core pieces of the story.ナラティブ更新 • Dec 15
VYGR: Cash Runway And Milestone Potential Will Drive Upside Ahead
Analysts have reduced their price target on Voyager Therapeutics by $5 to $25 per share, reflecting a modestly higher discount rate. They continue to highlight robust cash runway, significant milestone potential, and advancing NeuroShuttle data as key long term value drivers.分析記事 • Nov 15
Benign Growth For Voyager Therapeutics, Inc. (NASDAQ:VYGR) Underpins Stock's 26% Plummet
Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) shares have retraced a considerable 26% in the last month, reversing a fair...分析記事 • Nov 14
Earnings Update: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) just released its latest quarterly results and things are looking bullish...分析記事 • Sep 25
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Held Back By Insufficient Growth Even After Shares Climb 27%
Despite an already strong run, Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) shares have been powering on, with a gain of...分析記事 • May 27
It's Unlikely That The CEO Of Voyager Therapeutics, Inc. (NASDAQ:VYGR) Will See A Huge Pay Rise This Year
Key Insights Voyager Therapeutics' Annual General Meeting to take place on 3rd of June Salary of US$652.1k is part of...分析記事 • Feb 25
Positive Sentiment Still Eludes Voyager Therapeutics, Inc. (NASDAQ:VYGR) Following 27% Share Price Slump
Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) shareholders that were waiting for something to happen have been dealt a...Seeking Alpha • Jan 30
Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance
Summary Voyager Therapeutics, Inc.'s TRACER platform shows strong preclinical results for BBB-crossing gene therapies, securing multi-billion dollar deals with Novartis and Neurocrine, but lacks clinical trial data. VY7523, a monoclonal antibody for early Alzheimer's treatment, is expected to yield Phase I results by mid-2025, with potential undervaluation of VYGR shares. The competitive landscape includes Denali, Roche, and AbbVie, with varying BBB-crossing strategies, highlighting the speculative nature of investing in early-stage neurological therapies. I maintain a “Strong Buy” rating on VYGR shares for long-term, high-risk tolerant investors, emphasizing the speculative but promising potential of Voyager's TRACER platform and upcoming clinical trials. Read the full article on Seeking Alpha
新しいナラティブ • Jan 26
Developing Tau-Targeting Therapies Will Open Doors But May Encounter Setbacks
Strong partnerships and collaborations are expected to enhance revenue and earnings through milestone payments and shared R&D efforts.Seeking Alpha • Nov 18
Voyager Therapeutics' Tracer Platform Targets CNS Market: Here's Why I'm Neutral
Summary Voyager Therapeutics leverages its TRACER platform for targeted gene therapies, focusing on challenging CNS diseases like Alzheimer’s and ALS. Its pipeline includes a promising Phase 1 anti-tau Alzheimer’s therapy, VY7523, with data expected in 2025, but commercialization remains years away. Current valuation metrics indicate a balanced position, trading close to book value, suggesting potential but limited near-term catalysts. Key risks include reliance on collaboration revenues and the inherent difficulty of treating CNS disorders, warranting cautious optimism and a focus on future clinical trial updates. Despite promising technology and partnerships, VYGR faces long development timelines and challenging diseases, justifying a neutral "Hold" rating but worth watchlisting for 2025 R&D progress. Read the full article on Seeking Alpha分析記事 • Oct 17
Improved Revenues Required Before Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock's 27% Jump Looks Justified
Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) shareholders are no doubt pleased to see that the share price has bounced...Seeking Alpha • Aug 26
Voyager Therapeutics: CNS Player In Early Stages Of A Turnaround
Summary Shares are trading at relative lows (down 20% YTD), but have gained +130% over the past 3 years. Collaborations with big name partners like Novartis and Neurocrine have validated Voyager's TRACER AAV capsid platform. Enabling delivery across the blood brain barrier could be extended to additional modalities outside of gene therapy. The company is still at the "science project" phase of development, lacking a clear path to market, although I appreciate management's focus on indications where surrogate endpoints have gained acceptance. I remain on the sidelines and may revisit in the late 2025 to early 2026 timeframe when the pipeline has made more progress. Read the full article on Seeking Alpha分析記事 • Aug 09
Earnings Beat: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) just released its second-quarter report and things are looking bullish. The...分析記事 • Aug 08
Lacklustre Performance Is Driving Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Low P/S
With a price-to-sales (or "P/S") ratio of 2.7x Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) may be sending very bullish...Seeking Alpha • Jun 05
Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis
Summary Voyager Therapeutics, Inc. is a biotech company focused on developing gene-based therapies for neurological conditions. The company has made progress in its pipeline, including the start of the Phase 1 clinical trial for VY-TAU01, its Alzheimer's disease candidate. Voyager's strong revenue-driver partnerships and financial stability make it a "Strong Buy" for long-term investors. Read the full article on Seeking Alpha分析記事 • Mar 15
There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise
Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) shares have had a really impressive month, gaining 28% after a shaky period...Seeking Alpha • Mar 08
Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier
Summary Voyager Therapeutics, a drug delivery specialist focused on AAV vectors for gene therapies, has faced many challenges, including partners walking away from deals, disappointing data, and management changes. The company has recently gained momentum through new partnerships and drug programs, attracting more than $8 billion in potential development and commercial milestone payments from three major pharma partners. Voyager's unique TRACER Capsid discovery platform and focus on gene therapy delivery make it an intriguing investment opportunity in the biotech industry. Investors will need to be patient with this company as it targets hard-to-treat CNS disease such as Alzheimer's and Parkinson's, but it's at the forefront of a promising field and I believe its best days are ahead of it. Read the full article on Seeking Alpha分析記事 • Mar 04
What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates
Today is shaping up negative for Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) shareholders, with the analysts delivering...収支内訳
収支内訳
Voyager Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Jun 26 | 34 | -108 | 32 | 0 |
| 31 Mar 26 | 36 | -117 | 35 | 0 |
| 31 Dec 25 | 40 | -120 | 36 | 0 |
| 30 Sep 25 | 31 | -127 | 37 | 0 |
| 30 Jun 25 | 43 | -108 | 37 | 0 |
| 31 Mar 25 | 67 | -85 | 37 | 0 |
| 31 Dec 24 | 80 | -65 | 36 | 0 |
| 30 Sep 24 | 164 | 26 | 37 | 0 |
| 30 Jun 24 | 144 | 9 | 37 | 0 |
| 31 Mar 24 | 119 | -3 | 35 | 0 |
| 31 Dec 23 | 250 | 132 | 36 | 0 |
| 30 Sep 23 | 158 | 52 | 34 | 0 |
| 30 Jun 23 | 195 | 96 | 33 | 0 |
| 31 Mar 23 | 191 | 99 | 32 | 0 |
| 31 Dec 22 | 41 | -46 | 31 | 0 |
| 30 Sep 22 | 71 | -17 | 31 | 0 |
| 30 Jun 22 | 31 | -60 | 32 | 0 |
| 31 Mar 22 | 32 | -71 | 35 | 0 |
| 31 Dec 21 | 37 | -71 | 37 | 0 |
| 30 Sep 21 | 16 | -93 | 37 | 0 |
| 30 Jun 21 | 132 | 18 | 37 | 0 |
| 31 Mar 21 | 160 | 39 | 35 | 0 |
| 31 Dec 20 | 171 | 37 | 35 | 0 |
| 30 Sep 20 | 197 | 40 | 37 | 0 |
| 30 Jun 20 | 100 | -61 | 37 | 0 |
| 31 Mar 20 | 117 | -41 | 37 | 0 |
| 31 Dec 19 | 104 | -44 | 36 | 0 |
| 30 Sep 19 | 74 | -54 | 40 | 0 |
| 30 Jun 19 | 55 | -59 | 38 | 0 |
| 31 Mar 19 | 12 | -96 | 36 | 0 |
| 31 Dec 18 | 8 | -88 | 34 | 0 |
| 30 Sep 18 | 12 | -78 | 26 | 0 |
| 30 Jun 18 | 11 | -81 | 24 | 0 |
| 31 Mar 18 | 10 | -74 | 22 | 0 |
| 31 Dec 17 | 10 | -71 | 20 | 0 |
| 30 Sep 17 | 6 | -74 | 18 | 0 |
| 30 Jun 17 | 8 | -59 | 16 | 0 |
| 31 Mar 17 | 11 | -50 | 15 | 0 |
| 31 Dec 16 | 14 | -40 | 13 | 0 |
| 30 Sep 16 | 17 | -34 | 13 | 0 |
| 30 Jun 16 | 18 | -32 | 12 | 0 |
| 31 Mar 16 | 20 | -30 | 12 | 0 |
| 31 Dec 15 | 17 | -38 | 10 | 0 |
| 30 Sep 15 | 12 | -35 | 8 | 0 |
質の高い収益: VYGRは現在利益が出ていません。
利益率の向上: VYGRは現在利益が出ていません。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: VYGRは利益が出ておらず、過去 5 年間で損失は年間24.4%の割合で増加しています。
成長の加速: VYGRの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。
収益対業界: VYGRは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 64.6% ) と比較することは困難です。
株主資本利益率
高いROE: VYGRは現在利益が出ていないため、自己資本利益率 ( -69.78% ) はマイナスです。
総資産利益率
使用総資本利益率
過去の好業績企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/09/09 09:36 |
| 終値 | 2026/09/09 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Voyager Therapeutics, Inc. 11 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。24
| アナリスト | 機関 |
|---|---|
| Jack Allen | Baird |
| Brian Skorney | Baird |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |